한글목차

세계 폐암 진단 시장의 미래는 산업 시장과 의료 시장에서의 기회로 인해 유망한 것으로 평가되고 있습니다. 세계 폐암 진단 시장은 2025년부터 2031년까지 5.7%의 CAGR로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 전 세계 폐암 발병률 증가, 비침습적 액체 생검의 채택 증가, AI를 활용한 이미징 기술 도입 확대 등입니다.

• Lucintel의 예측에 따르면, 유형별로는 분자 분석이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 의료 분야가 높은 성장세를 보일 것으로 예상됩니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.

폐암 진단 시장의 새로운 동향

폐암 진단 시장은 현재 유전체학, 영상 진단, 인공지능의 발전에 힘입어 큰 전환점을 맞이하고 있습니다. 이러한 새로운 트렌드는 폐암 진단의 정확성, 접근성, 개별화를 크게 향상시켜 궁극적으로 환자 예후를 개선할 수 있을 것으로 기대됩니다.

• 액체 생검(Liquid Biopsy) 채택 : 혈액에서 순환 종양 DNA(ctDNA) 및 기타 바이오마커를 분석하는 액체 생검은 빠르게 부상하고 있는 추세입니다. 이 비침습적 방법은 조직 생검에 대한 부담이 적은 대안으로 조기 발견, 치료 반응 모니터링, 내성 기전 규명을 가능하게 하여 환자 관리에 혁명을 가져올 수 있습니다.
• 영상 진단의 AI와 머신러닝 : 인공지능(AI)과 머신러닝(ML)을 영상 진단(CT 스캔, 엑스레이)에 통합하는 것은 강력한 추세입니다. AI 알고리즘은 미묘한 결절의 검출을 강화하고, 위양성을 줄이고, 진단 정확도를 향상시키며, 영상의학과 전문의가 대량의 영상 데이터를 효율적으로 분석하여 조기에 정확한 진단을 내릴 수 있도록 돕습니다.
• 멀티오믹스 프로파일링 : 종합적인 폐암 진단을 위해 유전체, 단백질체, 메타볼롬 데이터를 결합한 멀티오믹스 프로파일링에 대한 관심이 높아지고 있습니다. 이 종합적인 접근법은 복잡한 분자 시그니처를 식별하고, 환자를 보다 정확하게 계층화하고, 우수한 결과를 위해 고도로 맞춤화된 치료 전략을 안내합니다.
• Point-of-Care 진단 : 빠르고 휴대가 간편하며 사용하기 쉬운 POC(Point-of-Care) 진단 장비의 개발은 특히 바이오마커 검출을 위한 새로운 트렌드입니다. 이 장비들은 비전문적인 환경에서도 신속한 스크리닝과 초기 진단을 가능하게 하며, 원격지나 자원이 제한된 지역에서의 진단 접근성을 향상시킵니다.
• 원격의료와의 통합 : 폐암 진단과 원격의료 플랫폼과의 통합은 가속화되는 추세입니다. 이를 통해 원격진료, 진단 영상 해석, 후속 조치, 전문가 의견에 대한 접근성을 개선하고, 특히 의료 혜택을 받지 못하는 사람들에게 필수적인 치료의 지리적 장벽을 낮출 수 있습니다.

이러한 추세는 덜 침습적이고, 더 정확하며, 고도로 개인화된 진단 접근방식으로 전환하면서 폐암 진단 시장을 크게 재편하고 있습니다. 또한, 접근성과 효율성을 향상시켜 궁극적으로 조기 발견율을 높이고, 보다 효과적이고 타겟팅된 치료 전략을 유도하고 있습니다.

폐암 진단 시장의 최근 동향

폐암 진단 시장은 최근 조기 발견의 세계 추진, 분자 생물학의 발전, 디지털 기술의 통합으로 인해 몇 가지 매우 중요한 추세를 목격했습니다. 이러한 변화는 진단 정확도 향상, 침습성 감소, 환자 예후 개선을 목표로 하고 있습니다.

• 저선량 CT 검진의 부상 : 저선량 컴퓨터 단층촬영(LDCT)이 고위험군 폐암 검진의 표준으로 전 세계적으로 채택되고 지지받고 있는 것은 중요한 진전입니다. 이를 통해 더 작고 치료 가능한 종양을 조기에 발견할 수 있게 되어 기존 방식에 비해 생존율이 크게 향상되었습니다.
• 액체 생검의 발전 : 최근 액체 생검의 급속한 발전과 임상적 유용성의 증가는 액체 생검의 빠른 발전과 임상적 유용성을 강조하고 있습니다. 이 비침습적 기술은 혈액 샘플에서 순환 종양 DNA(ctDNA), 순환종양세포(CTC) 및 기타 바이오마커를 검출할 수 있어 조기 진단, 맞춤형 치료 선택, 재발 모니터링이 가능합니다.
• 방사선 의학의 AI 통합 : 최근 주요 발전은 방사선 영상 진단에 인공지능(AI)과 머신러닝 알고리즘의 통합이 진행되고 있다는 점입니다. AI 기반 도구는 영상의학과 전문의가 의심스러운 폐 결절을 보다 정확하고 효율적으로 식별하고 특성화하여 위양성을 줄이고 진단 워크플로우를 개선할 수 있도록 돕습니다.
• 확장된 분자 프로파일링 : 폐암의 종합적인 분자 프로파일링은 단일 유전자 변이에 국한되지 않고 다유전자 패널과 차세대 염기서열 분석(NGS)을 포함한 종합적인 분자 프로파일링에 주목할 만한 진전을 보이고 있습니다. 이를 통해 종양의 보다 상세한 유전자 설계도를 얻을 수 있으며, 정밀 종양학에서 표적치료 및 면역치료의 지침으로 매우 중요합니다.
• 신규 바이오마커의 개발 : 최근 동향은 새로운 진단 및 예후 바이오마커의 발견과 검증을 포함합니다. 이러한 바이오마커에는 특정 단백질, 마이크로 RNA, 후생유전학적 마커 등이 포함되며, 다양한 플랫폼을 통해 검출함으로써 조기 진단 보조, 치료 반응 예측, 질병 진행 모니터링, 맞춤형 치료 강화로 이어질 수 있습니다.

이러한 치료법은 보다 적극적인 스크리닝, 덜 침습적인 진단 방법, 상세한 분자 정보에 기반한 고도로 개별화된 치료 접근법으로의 전환을 촉진하여 궁극적으로 환자 치료와 생존율을 개선함으로써 폐암 진단 시장에 큰 영향을 미치고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 성장 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 폐암 진단 시장 : 종류별

• 개요
• 매력 분석 : 종류별
• 면역분석법 : 동향과 예측(2019-2031년)
• 유세포 분석 : 동향과 예측(2019-2031년)
• 신속 검사 : 동향과 예측(2019-2031년)
• 분자 어세이 : 동향과 예측(2019-2031년)
• 조직 어레이 : 동향과 예측(2019-2031년)
• 순환종양세포 : 동향과 예측(2019-2031년)
• 약물 진단 : 동향과 예측(2019-2031년)
• 바이오마커 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제5장 세계의 폐암 진단 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 산업 : 동향과 예측(2019-2031년)
• 의료 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 폐암 진단 시장 : 지역별

제7장 북미의 폐암 진단 시장

• 개요
• 북미의 폐암 진단 시장 : 종류별
• 북미의 폐암 진단 시장 : 용도별
• 미국의 폐암 진단 시장
• 멕시코의 폐암 진단 시장
• 캐나다의 폐암 진단 시장

제8장 유럽의 폐암 진단 시장

• 개요
• 유럽의 폐암 진단 시장 : 종류별
• 유럽의 폐암 진단 시장 : 용도별
• 독일의 폐암 진단 시장
• 프랑스의 폐암 진단 시장
• 스페인의 폐암 진단 시장
• 이탈리아의 폐암 진단 시장
• 영국의 폐암 진단 시장

제9장 아시아태평양의 폐암 진단 시장

• 개요
• 아시아태평양의 폐암 진단 시장 : 종류별
• 아시아태평양의 폐암 진단 시장 : 용도별
• 일본의 폐암 진단 시장
• 인도의 폐암 진단 시장
• 중국의 폐암 진단 시장
• 한국의 폐암 진단 시장
• 인도네시아의 폐암 진단 시장

제10장 기타 지역(ROW)의 폐암 진단 시장

• 개요
• ROW의 폐암 진단 시장 : 종류별
• ROW의 폐암 진단 시장 : 용도별
• 중동의 폐암 진단 시장
• 남미의 폐암 진단 시장
• 아프리카의 폐암 진단 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간의 경쟁 관계
  • 구매자의 협상력
  • 공급업체의 협상력
  • 대체품의 위협
  • 신규 참여업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 종류별
  • 성장 기회 : 용도별
• 세계의 폐암 진단 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 인증·라이선싱
  • 기업 인수합병(M&A) , 계약, 제휴, 합작투자

제13장 밸류체인 전반에 걸친 주요 기업 개요

• 경쟁 분석
• Roche Diagnostics
• BioMerieux
• Qiagen
• Advpharma
• AIT Austrian Institute of Technology
• Courtagen Life Sciences
• DiagnoCure
• BioMark Diagnostics
• Mayo Clinic
• HalioDx SAS

제14장 부록

• 그림목차
• 표목차
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global lung cancer diagnostic market looks promising with opportunities in the industrial and healthcare markets. The global lung cancer diagnostic market is expected to grow with a CAGR of 5.7% from 2025 to 2031. The major drivers for this market are the increasing global lung cancer incidence rates, the rising adoption of non-invasive liquid biopsies, and the growing implementation of ai-driven imaging technologies.

• Lucintel forecasts that, within the type category, molecular assay is expected to witness the highest growth over the forecast period.
• Within the application category, healthcare is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market is currently at the cusp of a major transformation, fueled by advancements in genomics, imaging, and artificial intelligence. These emerging trends are significantly improving the accuracy, accessibility, and personalization of lung cancer diagnosis, ultimately leading to better patient outcomes.

• Liquid Biopsy Adoption: Liquid biopsy, which involves analyzing blood for circulating tumor DNA (ctDNA) or other biomarkers, is a rapidly emerging trend. This non-invasive method offers a less burdensome alternative to tissue biopsies, enabling earlier detection, monitoring treatment response, and identifying resistance mechanisms, thus revolutionizing patient management.
• AI and Machine Learning in Imaging: The integration of Artificial Intelligence (AI) and Machine Learning (ML) into diagnostic imaging (CT scans, X-rays) is a powerful trend. AI algorithms enhance the detection of subtle nodules, reduce false positives, and improve diagnostic accuracy, assisting radiologists in efficiently analyzing large volumes of imaging data for early and precise diagnosis.
• Multi-Omics Profiling: There's an increasing trend towards multi-omics profiling, combining genomic, proteomic, and metabolomic data for comprehensive lung cancer diagnosis. This holistic approach identifies complex molecular signatures, leading to more precise stratification of patients and guiding highly individualized therapeutic strategies for superior outcomes.
• Point-of-Care Diagnostics: The development of rapid, portable, and easy-to-use Point-of-Care (POC) diagnostic devices is an emerging trend, especially for biomarker detection. These devices enable quick screening and initial diagnosis in non-specialized settings, improving accessibility to diagnostics in remote or resource-limited areas.
• Integration with Telemedicine: The integration of lung cancer diagnostics with telemedicine platforms is an accelerating trend. This allows for remote consultation, interpretation of diagnostic images, and follow-up, improving access to specialist opinions and reducing geographical barriers to care, particularly vital for underserved populations.

These trends are profoundly reshaping the lung cancer diagnostic market by shifting towards less invasive, more accurate, and highly personalized diagnostic approaches. They are also improving accessibility and efficiency, ultimately enhancing early detection rates and guiding more effective, targeted treatment strategies.

Recent Developments in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market has witnessed several pivotal recent developments, primarily driven by a global push for early detection, advancements in molecular biology, and the integration of digital technologies. These changes aim to enhance diagnostic accuracy, reduce invasiveness, and improve patient outcomes.

• Rise of Low-Dose CT Screening: A significant development is the increasing global adoption and endorsement of Low-Dose Computed Tomography (LDCT) as the standard for lung cancer screening in high-risk individuals. This has led to earlier detection of smaller, more treatable tumors, significantly improving survival rates compared to traditional methods.
• Advancements in Liquid Biopsy: Recent developments highlight the rapid progress and increasing clinical utility of liquid biopsy. This non-invasive technology allows for the detection of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from blood samples, enabling early diagnosis, personalized treatment selection, and monitoring for recurrence.
• Integration of AI in Radiology: A key recent development is the growing integration of Artificial Intelligence (AI) and machine learning algorithms into radiological imaging. AI-powered tools assist radiologists in identifying and characterizing suspicious lung nodules more accurately and efficiently, reducing false positives and improving diagnostic workflows.
• Expanded Molecular Profiling: There's a notable development in the comprehensive molecular profiling of lung cancer, moving beyond single gene mutations to include multi-gene panels and next-generation sequencing (NGS). This provides a more detailed genetic blueprint of the tumor, crucial for guiding targeted therapies and immunotherapies in precision oncology.
• Development of Novel Biomarkers: Recent developments include the discovery and validation of new diagnostic and prognostic biomarkers. These include specific proteins, microRNAs, and epigenetic markers, which can be detected through various platforms to aid in early diagnosis, predict treatment response, and monitor disease progression, enhancing personalized care.

These developments are profoundly impacting the lung cancer diagnostic market by fostering a shift towards more proactive screening, less invasive diagnostic methods, and highly personalized treatment approaches based on detailed molecular information, ultimately improving patient care and survival rates.

Strategic Growth Opportunities in the Lung Cancer Diagnostic Market

The lung cancer diagnostic market offers substantial strategic growth opportunities across various key application areas, driven by the increasing global burden of lung cancer, continuous technological innovations, and a rising emphasis on early detection and personalized medicine. Identifying and capitalizing on these segments is crucial for market players to achieve sustainable growth.

• Early Lung Cancer Screening Programs: The expansion of population-based lung cancer screening programs using LDCT, particularly for high-risk individuals (e.g., heavy smokers), presents a significant growth opportunity. This drives demand for imaging equipment, AI-powered diagnostic software, and associated pathology services for nodule work-up.
• Personalized Medicine and Biomarker Testing: The accelerating shift towards personalized medicine in oncology creates a robust growth avenue. The demand for comprehensive biomarker testing (e.g., EGFR, ALK, PD-L1, KRAS) using molecular diagnostics (NGS, PCR) and liquid biopsies is paramount for guiding targeted therapies and immunotherapies.
• Post-Treatment Monitoring and Recurrence Detection: Providing diagnostic solutions for monitoring patients post-treatment and detecting early recurrence offers a strategic growth opportunity. Liquid biopsies, with their non-invasive nature, are increasingly valuable for serial monitoring of minimal residual disease and identifying emergent resistance mutations, guiding subsequent treatment decisions.
• Point-of-Care Diagnostics in Primary Care: The development and deployment of accessible point-of-care (POC) diagnostic tests, particularly for early symptom assessment or initial biomarker screening in primary care settings, presents a valuable opportunity. This can facilitate quicker referrals and reduce diagnostic delays, especially in underserved areas.
• Research and Drug Development Partnerships: Collaborating with pharmaceutical and biotechnology companies for companion diagnostics and clinical trial support offers a high-value, strategic growth opportunity. Developing diagnostic assays that identify patients most likely to respond to novel targeted therapies or immunotherapies is critical for drug development and regulatory approval.

These opportunities are profoundly impacting the lung cancer diagnostic market by shifting focus towards proactive screening, precision-based treatment guidance, continuous monitoring, and accessible diagnostic tools, thus expanding the market's reach and value across the entire patient journey.

Lung Cancer Diagnostic Market Driver and Challenges

The lung cancer diagnostic market is influenced by a dynamic interplay of various technological, economic, and regulatory factors. Understanding these primary drivers that propel market expansion and the significant challenges that may impede its growth is crucial for strategic decision-making by industry stakeholders.

The factors responsible for driving the lung cancer diagnostic market include:

1. Rising Incidence of Lung Cancer: The increasing global incidence of lung cancer, primarily due to factors like smoking, air pollution, and an aging population, is the most significant market driver. This escalating disease burden directly translates to a heightened demand for effective diagnostic tools and early detection strategies.

2. Growing Awareness for Early Detection: Increased public and physician awareness regarding the benefits of early lung cancer detection and the availability of screening programs (like LDCT) is a major driver. Public health campaigns and educational initiatives encourage high-risk individuals to undergo screening, boosting diagnostic volumes.

3. Technological Advancements in Diagnostics: Continuous innovations in diagnostic technologies, including high-resolution imaging, liquid biopsy, next-generation sequencing, and AI-powered analytics, are propelling market growth. These advancements lead to more accurate, less invasive, and faster diagnostic results, driving adoption.

4. Shift Towards Precision Medicine: The paradigm shift towards precision medicine in oncology significantly drives the demand for comprehensive diagnostic testing. Identifying specific genetic mutations and biomarkers is crucial for selecting targeted therapies and immunotherapies, leading to personalized and more effective treatment outcomes.

5. Favorable Reimbursement Policies: The increasing coverage and reimbursement for lung cancer screening (e.g., LDCT) and advanced molecular diagnostic tests by government and private payers are crucial market drivers. Favorable reimbursement policies enhance accessibility and affordability, encouraging broader adoption of diagnostic services.

Challenges in the lung cancer diagnostic market are:

1. High Cost of Advanced Diagnostics: The significant cost associated with advanced diagnostic technologies, such as comprehensive molecular profiling (NGS) and liquid biopsies, presents a major challenge. This can limit accessibility, particularly in developing regions or for patients without adequate insurance coverage, hindering widespread adoption.

2. Lack of Skilled Professionals: There is a global shortage of highly skilled healthcare professionals, including radiologists, pulmonologists, and molecular pathologists, trained in interpreting complex diagnostic tests and managing screening programs. This scarcity can impact the efficient implementation and scalability of advanced diagnostic services.

3. False Positives and Overdiagnosis: Lung cancer screening, particularly with LDCT, can lead to false-positive findings, necessitating additional invasive procedures and causing patient anxiety. The risk of overdiagnosis (detecting indolent tumors that would not have caused harm) also presents a challenge, requiring careful patient selection and management strategies.

The lung cancer diagnostic market is experiencing robust expansion, primarily fueled by the increasing global incidence of lung cancer, growing awareness for early detection, and rapid technological advancements, especially in precision medicine. However, significant challenges such as the high cost of advanced diagnostics, a shortage of skilled professionals, and concerns regarding false positives and overdiagnosis necessitate continuous innovation and strategic solutions to ensure equitable access and optimal patient care.

List of Lung Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies lung cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lung cancer diagnostic companies profiled in this report include-

• Roche Diagnostics
• BioMerieux
• Qiagen
• Advpharma
• AIT Austrian Institute of Technology
• Courtagen Life Sciences
• DiagnoCure
• BioMark Diagnostics
• Mayo Clinic
• HalioDx SAS

Lung Cancer Diagnostic Market by Segment

The study includes a forecast for the global lung cancer diagnostic market by type, application, and region.

Lung Cancer Diagnostic Market by Type [Value from 2019 to 2031]:

• Immunoassays
• Flow Cytometry
• Rapid Tests
• Molecular Assays
• Tissue Arrays
• Circulating Tumor Cells
• Pharmacodiagnostics
• Biomarkers
• Others

Lung Cancer Diagnostic Market by Application [Value from 2019 to 2031]:

• Industrial
• Healthcare
• Others

Lung Cancer Diagnostic Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Lung Cancer Diagnostic Market

The lung cancer diagnostic market is undergoing a transformative period, driven by advancements in early detection, precision medicine, and the integration of cutting-edge technologies. Recent developments focus on improving screening efficacy, developing non-invasive diagnostic tools, and identifying specific biomarkers to enable more personalized and effective treatment strategies for patients globally.

• United States: The U.S. market is heavily influenced by updated screening guidelines recommending low-dose CT for high-risk individuals. Recent developments include increased adoption of liquid biopsy for molecular profiling, growing interest in AI-powered image analysis to enhance diagnostic accuracy, and a strong push towards integrating these advanced diagnostics into clinical practice for personalized treatment.
• China: China lung cancer diagnostic market is rapidly expanding, with significant government support for early screening programs. Recent developments include widespread adoption of LDCT, increasing research and application of liquid biopsy for early detection and treatment monitoring, and a growing emphasis on AI-assisted diagnostics to manage the high volume of cases and improve efficiency.
• Germany: Germany has recently approved lung cancer screening as a benefit for statutory health insurance, signaling a major development. This will drive increased LDCT utilization. Recent developments also emphasize precision medicine, with growing use of molecular diagnostics for biomarker testing, alongside strong quality assurance requirements for screening programs, aligning with European healthcare standards.
• India: India lung cancer diagnostic market is growing due to increasing incidence and a push for early detection. Recent developments include initiatives like "LungLife" screening programs, increased adoption of LDCT, and a focus on identifying India-specific high-risk populations for targeted screening, with ongoing research into cost-effective blood-based biomarkers.
• Japan: Japan lung cancer diagnostic market is marked by technological sophistication and a focus on automation. Recent developments include extensive research and application of AI in analyzing CT images for nodule detection and characterization, with ultra-lightweight AI models being developed for accessible diagnostics, enhancing early detection efforts and reducing radiologist workload.

Features of the Global Lung Cancer Diagnostic Market

• Market Size Estimates: Lung cancer diagnostic market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Lung cancer diagnostic market size by type, application, and region in terms of value ($B).
• Regional Analysis: Lung cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, applications, and regions for the lung cancer diagnostic market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lung cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the lung cancer diagnostic market by type (immunoassays, flow cytometry, rapid tests, molecular assays, tissue arrays, circulating tumor cells, pharmacodiagnostics, biomarkers, and others), application (industrial, healthcare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Lung Cancer Diagnostic Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Immunoassays: Trends and Forecast (2019-2031)
• 4.4 Flow Cytometry: Trends and Forecast (2019-2031)
• 4.5 Rapid Tests: Trends and Forecast (2019-2031)
• 4.6 Molecular Assays: Trends and Forecast (2019-2031)
• 4.7 Tissue Arrays: Trends and Forecast (2019-2031)
• 4.8 Circulating Tumor Cells: Trends and Forecast (2019-2031)
• 4.9 Pharmacodiagnostics: Trends and Forecast (2019-2031)
• 4.10 Biomarkers: Trends and Forecast (2019-2031)
• 4.11 Others: Trends and Forecast (2019-2031)

5. Global Lung Cancer Diagnostic Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Industrial: Trends and Forecast (2019-2031)
• 5.4 Healthcare: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Lung Cancer Diagnostic Market by Region

7. North American Lung Cancer Diagnostic Market

• 7.1 Overview
• 7.2 North American Lung Cancer Diagnostic Market by Type
• 7.3 North American Lung Cancer Diagnostic Market by Application
• 7.4 United States Lung Cancer Diagnostic Market
• 7.5 Mexican Lung Cancer Diagnostic Market
• 7.6 Canadian Lung Cancer Diagnostic Market

8. European Lung Cancer Diagnostic Market

• 8.1 Overview
• 8.2 European Lung Cancer Diagnostic Market by Type
• 8.3 European Lung Cancer Diagnostic Market by Application
• 8.4 German Lung Cancer Diagnostic Market
• 8.5 French Lung Cancer Diagnostic Market
• 8.6 Spanish Lung Cancer Diagnostic Market
• 8.7 Italian Lung Cancer Diagnostic Market
• 8.8 United Kingdom Lung Cancer Diagnostic Market

9. APAC Lung Cancer Diagnostic Market

• 9.1 Overview
• 9.2 APAC Lung Cancer Diagnostic Market by Type
• 9.3 APAC Lung Cancer Diagnostic Market by Application
• 9.4 Japanese Lung Cancer Diagnostic Market
• 9.5 Indian Lung Cancer Diagnostic Market
• 9.6 Chinese Lung Cancer Diagnostic Market
• 9.7 South Korean Lung Cancer Diagnostic Market
• 9.8 Indonesian Lung Cancer Diagnostic Market

10. ROW Lung Cancer Diagnostic Market

• 10.1 Overview
• 10.2 ROW Lung Cancer Diagnostic Market by Type
• 10.3 ROW Lung Cancer Diagnostic Market by Application
• 10.4 Middle Eastern Lung Cancer Diagnostic Market
• 10.5 South American Lung Cancer Diagnostic Market
• 10.6 African Lung Cancer Diagnostic Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Lung Cancer Diagnostic Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Roche Diagnostics
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 BioMerieux
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Qiagen
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Advpharma
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 AIT Austrian Institute of Technology
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Courtagen Life Sciences
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 DiagnoCure
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 BioMark Diagnostics
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Mayo Clinic
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 HalioDx SAS
  • Company Overview
  • Lung Cancer Diagnostic Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us